Aytu Biopharma (AYTU) Current Deferred Revenue (2014 - 2020)

Aytu Biopharma (AYTU) has reported Current Deferred Revenue for 6 consecutive years, with $475680.0 the latest figure, recorded in Q4 2020.

• On a quarterly basis, Current Deferred Revenue changed N/A year-over-year to $475680.0 in Q4 2020; TTM through Dec 2020 was $475680.0, a N/A change from a year earlier, with the FY2020 full-year figure at $339336.0, changed N/A from the prior year.
• Current Deferred Revenue was $475680.0 for Q4 2020 at Aytu Biopharma, up from $232576.0 in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $475680.0 in Q4 2020 and troughed at $1450.0 in Q2 2018.
• A 4-year average of $145070.9 and a median of $13990.0 in 2018 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue jumped 397.0% in 2016 and slumped 98.43% in 2017, its largest moves.
• Over 4 years, Current Deferred Revenue stood at $426000.0 in 2016, then tumbled by 98.88% to $4787.0 in 2017, then surged by 192.25% to $13990.0 in 2018, then jumped by 3300.14% to $475680.0 in 2020.
• The last three Current Deferred Revenue figures came in at $475680.0 (Q4 2020), $232576.0 (Q3 2020), and $339336.0 (Q2 2020), per Business Quant data.